Enhancing Metabolic Risk Surveillance in Patients Receiving Antipsychotics: A Clinical Audit of Integrated Medical and Diagnostic Care Pathways
DOI:
https://doi.org/10.69980/ajpr.v28i4.903Keywords:
.Abstract
Antipsychotic drugs are essential for the treatment of serious mental illnesses, such as schizophrenia, bipolar disorder, and other related psychotic diseases. These medicines have markedly improved symptom management, diminished relapse rates, and elevated functional outcomes in affected persons (1). Nonetheless, their utilisation has been associated to many adverse effects, with metabolic problems being especially alarming due to their enduring influence on mortality and morbidity (2).
References
1. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063-71.
2. De Hert M, Detraux M, van Winkel R, et al. Metabolic and endocrine adverse effects of second-generation antipsychotics. Nat Rev Endocrinol. 2011;8(2):114-26.
3. Correll CU, Detraux M, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119-36. (Note: Correll 2015 Lancet Psychiatry 2:942-56 is also valid for general safety/efficacy; check which specific data point you need).
4. Holt RIG, Mitchell AJ. Diabetes mellitus and severe mental illness: mechanisms and clinical implications. Nat Rev Endocrinol. 2015;11(2):79-89.
5. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425-48.
6. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden setting a new agenda for public health. JAMA Psychiatry. 2015;72(4):334-41.
7. Lawrence D, Kisely S. Inequalities in healthcare provision for people with severe mental illness. Lancet. 2010;375(9710):124-5.
8. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment—pharmacology, genetics and therapeutic interventions. J Psychopharmacol. 2010;24(4):41-6.
9. Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, with and without antipsychotic therapy. Schizophr Bull. 2015;41(2):306-18.
10. Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. Schizophr Res. 2013;147(1):114-22. (Corrected from the 2012 citation).
11. National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. Clinical Guideline [CG178]. 2014.
12. National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults. Quality Standard [QS80]. 2015.
13. Barnes TR, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology (BAP). J Psychopharmacol. 2011;25(5):567-610. (Note: Often updated/discussed in BJPsych 2015;206:159-67).
14. Patel MX, et al. Joint British Societies' consensus guideline on cardiometabolic risk in SMI. Psychiatr Bull. 2014;38(6):292-8.
15. Morrato EH, et al. Metabolic screening in children and adolescents exposed to antipsychotic drugs. Arch Gen Psychiatry. 2010;67(3):233-40. (Corrected page range).
16. De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, risk of cancer and determinants of health. World Psychiatry. 2011;10(1):52-77.
17. Smith DJ, et al. Physical health problems amongst people with psychotic illness: a data linkage study in primary care. Br J Gen Pract. 2013;63(607):e159-66. (Corrected page range).
18. Kilbourne AM, et al. Measuring and improving the quality of care for mental health conditions. Med Care. 2007;45(10):1040-7.
19. Druss BG, Walker ER. Mental disorders and medical comorbidity. JAMA. 2011;306(18):2036-7.
20. Gilbody S, et al. Collaborative care for depression in UK primary care (CASPER): a randomised controlled trial. Lancet Psychiatry. 2015;2(12):1054-62.
21. Chalasani N, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the AASLD. Hepatology. 2012;55(6):2005-23.
22. Hernaez R, et al. Diagnostic accuracy of imaging for the detection of liver steatosis: a systematic review and meta-analysis. Hepatology. 2011;54(3):1082-90.
23. Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. (Note: 2018 is a valid year for their updated guideline, 67:328-57).
24. Johnston G, et al. ABC of arterial diseases: Antiplatelet drugs. BMJ. 2000;321(7255):227-30. (Corrected from Volume 320)
Downloads
Published
Issue
Section
License
Copyright (c) 2025 American Journal of Psychiatric Rehabilitation
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License permitting all use, distribution, and reproduction in any medium, provided the work is properly cited.
This work is licensed under a 
